The Rome III classification of dyspepsia: Will it help research?

Digestive Diseases

Volumn 26, Issue 3, 2008, Pages 203-209

  Talley, Nicholas J ^a,b   Ruff, Kevin ^b   Jiang, Xuan ^b   Jung, Hye Kyung ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

Dyspepsia; Functional dyspepsia; Functional gastrointestinal disorder; Non ulcer dyspepsia

Indexed keywords

CLONIDINE; LANSOPRAZOLE; NITRIC OXIDE DONOR; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; SUMATRIPTAN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; DISEASE CLASSIFICATION; DYSPEPSIA; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; POSTPRANDIAL DISTRESS SYNDROME; PRIORITY JOURNAL; REVIEW; ROME 3 CLASSIFICATION;

DYSPEPSIA; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HELICOBACTER INFECTIONS; HUMANS; MALE; POSTPRANDIAL PERIOD; PROGNOSIS; RESEARCH;

EID: 43449122181     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121347     Document Type: Review

References (45)

1. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390.
2. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479.
3. Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyren O, Stanghellini V: Functional dyspepsia. A classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145-160.
4. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN: Functional gastroduodenal disorders. Gut 1999;45 (suppl 2):II37-II42.
5. Gilvarry J, Buckley MJM, Beattie S, Hamilton H, O'Morain CA: Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997;32:535-540.
6. Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, Kordecki H, Schmid V: Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-1065.
7. Holtmann G, Stanghellini V, Talley NJ: Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying the concepts. Baillière's Clin Gastroenterol 1998;12:417-433.
8. Camilleri M, Dubois D, Coulie B, Jones M, Kahrilas PJ, Rentz AM, Sonnenberg A, Stanghellini V, Stewart WF, Tack J, Talley NJ, Whitehead W, Revicki DA: Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3:543-552.
9. Laheij RJ, De Koning RW, Horrevorts AM, Rongen RJ, Rossum LG, Witteman EM, Hermsen JT, Jansen JB: Predominant symptom behavior in patients with persistent dyspepsia during treatment. J Clin Gastroenterol 2004;38:490-495.
10. Meineche-Schmidt V, Jorgensen T: Fluctuation in dyspepsia subgroups over time. A three-year follow-up of patients consulting general practice for dyspepsia. Dig Liver Dis 2002;34:332-338.
11. Karamanolis G, Caenepeel P, Arts J, Tack J: Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006;130:296-303.
12. Nyren O, Adami HO, Gustavsson S, Lindgren PG, Loof L, Nyberg A: The 'epigastric distress syndrome'. A possible disease entity identified by history and endoscopy in patients with nonulcer dyspepsia. J Clin Gastroenterol 1987;9:303-309.
13. Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, Chiba N, Thomson AB, Smyth S, Sinclair P, Chakraborty B, White RJ; The CADET-HR Study Group. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care - the CADET-HR Study. Aliment Pharmacol Ther 2005;21:1189-1202.
14. Ford AC, Forman D, Bailey AG, Cook MB, Axon AT, Moayyedi P: Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol 2007;102:957-965.
15. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D, Janssens J: Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005;54:1370-1376.
16. Locke GR 3rd, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ:Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005;17:29-34.
17. Thomson AB, Barkun AN, Armstrong D, Chiba N, White RJ, Daniels S, Escobedo S, Chakraborty B, Sinclair P, Van Zanten SJ: The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia:the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-1491.
18. des Varannes SB, Sacher-Huvelin S, Vavasseur F, Masliah C, Le Rhun M, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP: Rabeprazole test for the diagnosis of gastrooesophageal reflux disease: results of a study in a primary care setting. World J Gastroenterol 2006;12:2569-2573.
19. Talley NJ, Locke GR 3rd, Lahr BD, Zinsmeister AR, Tougas G, Ligozio G, Rojavin MA, Tack J: Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut 2006;55:933-939.
20. Talley NJ, Verlinden M, Jones M:Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol 2001;96:1422-1428.
21. Tack J, Bisschops R, Sarnelli G: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239-1255.
22. Tack J, Demedts I, Dehondt G, Caenepeel P, Fischler B, Zandecki M, Janssens J: Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002;122:1738-1747.
23. Mizuta Y, Isomoto H and Takahashi T: Impaired nitrergic innervation in rat colitis induced by dextran sulfate sodium. Gastroenterology 2000;118:714-723.
24. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346-1352.
25. Fischler B, Tack J, De Gucht V, Shkedy ZI, Persoons P, Broekaert D, Molenberghs G, Janssens J: Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia, Gastroenterology 2003;124:903-910.
26. Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR, Agreus L: Non-ulcer dyspepsia and duodenal eosinophilia. An adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1175-1183.
27. Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J: Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 2003;52:1271-1277.
28. Gonenne J, Castillo EJ, Camilleri M, Burton D, Thomforde GM, Baxter KL, Zinsmeister AR: Does the nutrient drink test accurately predict postprandial gastric volume in health and community dyspepsia? Neurogastroenterol Motil 2005;17:44-50.
29. Choung RS, Talley NJ, Peterson J, Camilleri M, Burton D, Harmsen WS, Zinsmeister AR: A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007;19:180-187.
30. Talley NJ, Camilleri M, Burton D, Thomforde G, Koch K, Rucker MJ, Peterson J, Zinsmeister AR, Earnest DL: Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. Aliment Pharmacol Ther 2006;24:859-867.
31. Gautier JF, Chen K, Salbe AD, Bandy D, Pratley RE, Heiman M, Ravussin E, Reiman EM, Tataranni PA: Differential brain responses to satiation in obese and lean men. Diabetes 2000;49:838-846.
32. Ladabaum U, Roberts TP, McGonigle DJ: Gastric fundic distension activates frontolimbic structures but not primary somatosensory cortex: a functional magnetic resonance imaging study. Neuroimage 2007;34:724-732.
33. Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkhoff H, Eaker E, Ohning G, Miner PB, Mathias JR, Fumagalli I, Staessen D, Mack RJ: Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:1653-1661.
34. Halder SL, Talley NJ: Treatment of functional dyspepsia. Curr Treat Options Gastroenterol 2005;8:325-336.
35. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ: Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004;116:740-748.
36. Bolling-Sternevald E, Lauritsen K, Aalykke C, Havelund T, Knudsen T, Unge P, Ekstrom P, Jaup B, Norrby A, Stubberod A, Melen K, Carlsson R, Jerndal P, Junghard O, Glise H: Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002;37:1395-1402.
37. Jones RH, Baxter G: Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997;11:541-546.
38. Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, Kordecki H, Schmid V: Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-1065.
39. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003;1:CD001960.
40. Tack J, Vos R, Janssens J, Salter J, Jauffret S, Vandeplassche G: Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003;18:1031-1037.
41. Bisschops R, Tack J: Dysaccommodation of the stomach:therapeutic nirvana? Neurogastroenterol Motil 2007;19:85-93.
42. Suzuki H, Nishizawa T, Hibi T: Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 2006;41:513-523.
43. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD: Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003;98:2454-2459.
44. Locke GR 3rd, Zinsmeister AR, Fett SL, Melton LJ 3rd, Talley NJ: Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005;17:29-34.
45. Jung HK, Halder S, McNally M, Locke GR 3rd, Schleck C, Zinsmeister AR, Talley NJ: Overlap of gastroesophageal reflux disease and irritable bowel syndrome: Prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007;26:453-461.